CA3179048A1 — Use of bupropion and dextromethorphan combinations for treating neurological disorders
Assigned to Antecip Bioventures II LLC · Expires 2021-10-07 · 5y expired
What this patent protects
Methods for the treatment of major depressive disorder or agitation associated with Alzheimer's disease comprising the administration of a combination therapy comprising bupropion and dextromethorphan are provided. Particular provided methods comprise the administration of about …
USPTO Abstract
Methods for the treatment of major depressive disorder or agitation associated with Alzheimer's disease comprising the administration of a combination therapy comprising bupropion and dextromethorphan are provided. Particular provided methods comprise the administration of about 105 mg bupropion hydrochloride and about 45 mg dextromethorphan hydrobromide, once or twice daily, to a human subject who is about 41 years of age or older.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.